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Abstract. Dermtrainer is a medical decision support system that assists general
practitioners in diagnosing skin diseases and serves as a training platform for der-
matologists. Its key components are a comprehensive dermatological knowledge
base, a clinical algorithm for diagnosing skin diseases, a reasoning component for
deducing the most likely differential diagnoses for a patient, and a library of high-
quality images. This report describes the technical components of the system, in
particular the ranking algorithm for retrieving appropriate diseases as diagnoses.
1. Motivation
Skin diseases, most prominently skin cancer, pose a significant burden on public health,
with incidences continually increasing [4]. Early recognition and knowledge about the
epidemiology of the various skin diseases are prerequisites to treat them effectively and
to prevent fatal outcomes [2]. These necessities face two major obstacles: In many areas
of the world dermatology specialists are rare, and non-specialists are responsible for
diagnosing skin diseases. Moreover, within Europe, training programs for dermatologists
vary substantially between countries.
Available diagnostic decision support tools for dermatology often perform simple
data retrieval without any reasoning component [7], are cumbersome to use, frequently
yield poor results [1], and lack scientific validation [6]. The objective of the project
Dermtrainer (funded by FFG, 2013–2015) was to develop a medical decision support
system that serves as a training platform for dermatologists and assists general practi-
tioners in diagnosing skin diseases.
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type fields examples
number & arrangement 22 single/multiple, localized/widespread
location 17 neck, arm, abdomen
morphology 37 papule, ulcer, arciform
color 16 single/multiple, white, blue
timing 11 acute, chronic, recurrent
demographics 8 age groups, skin type
signs & symptoms 19 general appearance, additional signs
epidemiology 3 frequency, gender ratio
Table 1. Overview of the fields relevant for ranking a disease
2. Consortium
Dermatologists from the Medical University of Vienna – headed by Elisabeth Riedl who
was also overall coordinator – contributed a clinical algorithm (a systematic procedure
for diagnosing skin diseases) and entered data describing skin diseases into a knowledge
databases. They were also in charge of a clinical validation study comparing the diag-
nostic accuracy of non-specialized physicians when using Dermtrainer vs. a standard
encyclopedia (manuscript in preparation at time of submission).
Software engineers from the company Emergentec Biodevelopment – coordinated
by Arno Lukas – developed the user interface as well as the infrastructure for storing and
maintaining data and images. Moreover, they provided computer support for the clinical
validation study.
Computer scientists from Technische Universität Wien – coordinated by Gernot
Salzer – analyzed the meaning of the data, devised, implemented, and evaluated methods
for selecting appropriate diagnoses based on patient data, and provided a tool that helped
in debugging the disease data.
3. User interface
Physicians enter data of a patient case via a web interface in seven steps, providing
information on the arrangement, localization, morphology, and color of the observed
lesions as well as timing information and additional signs (Figure 1). It is not necessary to
fill the forms completely, but more input data potentially leads to more accurate rankings.
4. Knowledge Database
The knowledge database (at the time of conclusion of the Austrian Research Promotion
Agency (FFG) project) contains the data of 620 diseases. Each is represented by 150
fields, of which 133 correspond to symptoms that are used for ranking (Table 1) and 17
provide supplementary information.
4.1. Likelihood
Most values in the database approximate the conditional probability P (s | d) that the
symptom s is observed in the case that the patient has the disease d. In a perfect world
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Figure 1. The patient data is entered in seven steps, starting with basic information like age and sex, continuing
with arrangement, morphology, location, and color of lesions, and concluding with timing information and
additional signs.
judgement meaning likelihood L(s, d)
yes The symptom occurs with the disease. 1.0
unlikely In rare cases the symptom can be observed with the disease. 0.02
no The symptom never occurs with the disease, but the disease should remain
in the ranking.
0.001
no The symptom never occurs with the disease, the disease can be excluded
from ranking.
0.0
Table 2. Judgements regarding whether a symptom may occur with a disease. The likelihood is used later on
for ranking.
we would know this probability for each symptom and each disease. In reality, virtually
none of the more than 80 000 values can be determined with absolute certainty. They
are replaced by one of three judgements, estimated by the dermatologists: “yes, this
symptom occurs with the disease”, “no, it does not”, and “this symptom is unlikely to
occur, but it may” (Table 2). For the purpose of ranking, we represent the judgements by
numerical values that we call likelihood (to avoid the term probability); L(s, d) denotes
the likelihood that the symptom s occurs with disease d. This fuzzy knowledge is one of
the main challenges for automated diagnosis.
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frequency F (d)
exceptional 10−7
rare 10−6
uncommon 10−5
less common 10−4
common 10−3
very common 10−2
Table 3. Frequency of diseases
4.2. Simplified Likelihood
For demographics (predominant age group and skin type) and location (body sites where
lesions occur) the judgement “unlikely” is not used. The database only contains infor-
mation about whether or not the disease occurs among persons having a specific skin
type or age, or whether the lesions are confined to specific sites of the body. There is no
distinction between “yes” and “unlikely”.
4.3. Epidemiology
There are a few elements with higher precision, most notably the overall frequency of the
disease and the sex ratio, extracted from literature and expert knowledge. The frequency
is specified on a 6-level scale from “exceptional” to “very common” (Table 3). If a dis-
ease is known to affect one sex more frequently than the other, it is possible to specify
a male : female ratio. E.g., the ratio 2 : 1 indicates that the disease occurs twice as often
among men, while 0 : 1 indicates that the disease occurs exclusively among women.
5. Ranking
Diseases are ranked in three phases.
Phase 1: Exclusion of Diseases
The number of diseases is reduced to typically less than a hundred by eliminating dis-
eases where certain symptoms selected in the user interface correspond to a “no” value in
the disease record: If a particular symptom never occurs with a disease, then the disease
can be excluded as a potential diagnosis.
Unfortunately, this approach only works for some symptoms that cannot be mis-
taken. In preliminary testing, we found that judgements of non-specialists may differ
considerably from the opinion of dermatologists who defined the disease specifications,
leading to spurious exclusion of diseases by mistaking single symptoms.
We therefore distinguish between exclusive and non-exclusive symptoms. Exclusive
symptoms are those that can be classified beyond doubt. For such symptoms the judge-
ment “no” will exclude the disease from the list of diagnoses. An example for an ex-
clusive symptom is the number of lesions: If the patient shows just a single lesion, dis-
eases that always go with multiple lesions are excluded from further consideration. For
non-exclusive symptoms “no” is not a strict “no” but rather a “even more unlikely than
4
Figure 2. Sample view of a disease ranking after entering symptom attributes. Warning signs mark diseases
prespecified as severe.
unlikely”. The disease is penalized, but stays in the ranking and may still become a top
diagnosis if other symptoms make up for the penalty.
In most cases, a symptom is exclusive for all diseases or for none. Locations are
an exception, as their exclusiveness can be specified independently per disease. It is
possible to specify for a disease that the judgement “no” for a location like the head is
to be interpreted strictly: If the patient shows a lesion there, the disease is excluded as
diagnosis. Other diseases may handle the location more liberally and just downgrade a
disease if the observed lesion is in the wrong place.
Phase 2: Scoring
In the second phase we compute scores that reflect how well each of the non-excluded
diseases matches the provided symptoms. After evaluating several approaches, including
term frequency-inverse document frequency (tf-idf) [5] many-valued logics, we finally
settled on a method that is based on a probabilistic interpretation of the data. It yields
two numbers per disease, one called similarity that ignores epidemiology, and one called
rank that combines similarity with the overall frequency of the disease. The details of
the method are presented in sections 6 and 7.
Phase 3: Selection
In the third phase we select the diseases with the highest scores regarding similarity and
rank (above a fixed threshold) and display them as the possible diagnoses. Even though
the diagnoses are displayed in the order of their internal ranking, we avoid to show ranks
and scores, as these numbers would convey a wrong sense of precision, and might be
mistaken as actual probabilities (Figure 2).
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6. A Ranking Method Based on Bayes’ Theorem
We use a method sometimes referred to as naïve Bayes classification, which relies on
Bayes’ theorem with strong independence assumptions [3].
Given a patient with particular symptoms, the aim is to assign a rank to each disease
that indicates how well the symptoms are explained by the disease. One approach is
to use P (d | s1, . . . , sn), the conditional probability of disease d given the symptoms
s1, . . . , sn, as the rank of d. According to Bayes’ theorem it can be computed as
P (d | s1, . . . , sn) = P (s1, . . . , sn | d) · P (d)
P (s1, . . . , sn)
(1)
where
P (d | s1, . . . , sn) probability of the patient having disease d if showing the symptoms
s1, . . . , sn
P (s1, . . . , sn | d) probability of observing all of the symptoms s1, . . . , sn simultane-
ously if the patient has disease d
P (d) probability of disease d
P (s1, . . . , sn) probability of observing all of the symptoms s1, . . . , sn simultane-
ously (caused by whatever disease)
Note that we are not interested in the probability P (d | s1, . . . , sn) itself but rather in
the relative order of diseases with respect to this value. This order is maintained when
multiplying the probability with a constant. P (s1, . . . , sn) is such a constant since it is
independent of any particular disease. Therefore we define the rank rank(d | s1, . . . , sn)
of a disease d for symptoms s1, . . . , sn as
rank(d | s1, . . . , sn) = P (d | s1, . . . , sn) · P (s1, . . . , sn) (2)
= P (s1, . . . , sn | d) · P (d) (3)
We assume the symptoms to be independent from each other. This allows us to replace
P (s1, . . . , sn | d) by P (s1 | d) · · ·P (sn | d). Strictly speaking most symptoms are not in-
dependent, but the correlation is weak. The simplification is also justified ex post by the
good results of the final evaluation of the algorithm. Thus equation (3) can be rewritten
as
rank(d | s1, . . . , sn) = P (s1 | d) · · · · · P (sn | d) · P (d) (4)
where
rank(d | s1, . . . , sn) rank of disease d given the symptoms s1, . . . , sn
P (si | d) conditional probability of observing symptom si given disease d
P (d) unconditional probability for disease d
Determining precise values for P (si | d) and P (d) is virtually impossible, as it would
require extensive medical studies for all combinations of symptoms and diseases. There-
fore we use approximations P˜ (si | d) and P˜ (d) derived from the qualitative information
in the database.
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rank(d | s1, . . . , sn) = P˜ (s1 | d) · · · · · P˜ (sn | d) · P˜ (d) (5)
Some symptoms may turn out to be more relevant for diagnosing than others. This can
be modeled by attaching weights to the symptoms; in a multiplicative formula this means
to add exponents.
rank(d | s1, . . . , sn) = P˜ (s1 | d)w1 · · · · · P˜ (sn | d)wn · P˜ (d) (6)
The first part of expression (6) quantifies how well the disease fits the symptoms, regard-
less of its frequency. We call this part similarity. This leads us to the final formula that
serves as the basis of the ranking algorithm.
rank(d | s1, . . . , sn) = similarity(s1, . . . , sn | d) · P˜ (d) (7)
similarity(s1, . . . , sn | d) = P˜ (s1 | d)w1 · · · · · P˜ (sn | d)wn (8)
where
rank(d | s1, . . . , sn) weighted rank of disease d given the symptoms s1, . . . , sn
similarity(s1, . . . , sn | d) similarity between symptoms s1, . . . , sn and disease d
P˜ (si | d) approximate probability of observing symptom si given dis-
ease d
P˜ (d) approximate probability of disease d
w1, . . . , wn weights of the symptoms s1, . . . , sn; choose w1 = · · · =
wn = 1 for no weighting
7. From Judgements to Approximate Probabilities
In this section we discuss how to obtain the approximations P˜ (si | d) and P˜ (d) in equa-
tions (7) and (8) from the disease database.
7.1. Categories of Symptoms
A category is a group of symptoms that are considered simultaneously. The symptoms
of a category may be mutually exclusive, meaning that the user can select at most one.
If several ones can be selected, their average is computed in order to give equal weight
to the categories, independent of the number of symptoms they are comprised of and the
number of symptoms that have been selected. The above mentioned constraints for the
selection of symptoms as well as dependencies between categories are hard-wired into
the user interface and are automatically enforced.
Example 1. The category predominant age group contains the five ‘symptoms’ infant,
child, adolescent, adult, and elder, of which only one can be selected. Likewise, the
symptoms localized and widespread in the category distribution are mutually exclusive.
Example 2. In category form, any number of the symptoms domeShaped, flatTopped,
and umbilicated may be selected simultaneously.
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7.2. Computing the Approximate Probability of a Category
Let s1, . . . , sn be all symptoms of a category, and let t1, . . . , tk be the symptoms actu-
ally observed. The approximate probability for these observations under the assumption
that the patient has disease d, denoted by P˜ (t1, . . . , tk | d), is obtained by the following
formula.
P˜ (t1, . . . , tk | d) =
k
√
L(t1, d) · · · · · L(tk, d)
L(s1, d) + · · ·+ L(sn, d) (9)
Multiplying these approximate probabilities for all categories of a disease yields its sim-
ilarity with respect to the observed symptoms (compare equation (8) above).
Example 3. Consider the symptoms s1 = domeShaped, s2 = flatTopped, and
s3 = umbilicated of category form. Suppose the patient shows the symptoms t1 =
domeShaped and t2 = umbilicated . For the disease d = Atypical fibroxanthoma the ex-
pert judgement for the symptoms domeShaped and flatTopped is ‘yes’, whereas umbili-
cated is considered ‘unlikely’. The corresponding likelihoods are L(s1, d) = L(t1, d) =
L(s2, d) = 1.0 and L(s3, d) = L(t2, d) = 0.02. Hence we obtain:
P˜ (domeShaped, umbilicated |Atypical fibroxanthoma) (10)
=
2
√
L(t1, d) · L(t2, d)
L(s1, d) + L(s2, d) + L(s3, d)
(11)
=
2
√
1.0 · 0.02
1.0 + 1.0 + 0.02
(12)
= 0.07 (13)
7.3. Epidemiology
To compute the rank of a disease, we have to multiply its similarity with its probability
(equation (7)). The probability P (d) is approximated by the frequency of the disease in
Table 3.
P˜ (d) = F (d) (14)
8. Evaluation
Evaluation was done in three stages. First, dermatologists participating in the project
tested the tool with retrospective cases from their practice for plausibility of results.
Unreasonable rankings were analyzed, leading to further modifications in the database
and improvements of the ranking algorithms.
For the subsequent evaluations, virtual patient cases were created consisting of the
most common and important skin diseases. The second stage was performed on derma-
tology residents of a single center to test the feasibility of the system, and the third stage
on non-dermatology residents (publications pending).
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One limitation of the evaluations so far has been the necessity to rely on virtual
patients for ethical reasons. Symptoms like the three-dimensional form – plane, eleva-
tion, depression, opening – or the consistency – soft, firm, indurated – are hard to judge
from an image. A dermatologist can make up for it by matching the images with real
cases from the past, but non-experts, one of the target groups, will probably often guess
wrongly. We expect that Dermtrainer will perform better with real patients, when such
symptoms can be correctly determined.
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